CD20 anticorps (FITC)
-
- Antigène Voir toutes CD20 (MS4A1) Anticorps
- CD20 (MS4A1) (Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))
-
Reactivité
- Humain
-
Hôte
- Souris
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp CD20 est conjugé à/à la FITC
-
Application
- Flow Cytometry (FACS)
- Specificité
- The antibody LT20 reacts with an extracellular epitope of CD20 (Bp35), a 33-37 kDa non-glycosylated membrane receptor with four transmembrane domains, expressed on B lymphocytes (it is lost on plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes.
- Réactivité croisée (Details)
- Human
- Purification
- Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
- Immunogène
- Normal human lymphocytes from lymph node.
- Clone
- LT20
- Isotype
- IgG2a
- Top Product
- Discover our top product MS4A1 Anticorps primaire
-
-
- Indications d'application
- Flow cytometry: The reagent is designed for analysis of human blood cells using 20 μL reagent / 100 μL of whole blood or 106 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
- Commentaires
-
The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.
- Restrictions
- For Research Use only
-
- Reconstitution
- No reconstitution is necessary.
- Buffer
- Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Conseil sur la manipulation
-
Do not freeze.
Avoid prolonged exposure to light. - Stock
- 4 °C
- Stockage commentaire
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
Analysis of B-cell subpopulations in monoclonal gammopathies." dans: Clinical lymphoma, myeloma & leukemia, Vol. 15, Issue 4, pp. e61-71, (2015) (PubMed).
: "Fluorescent immunoprecipitation analysis of cell surface proteins: a methodology compatible with mass-spectrometry." dans: Journal of immunological methods, Vol. 319, Issue 1-2, pp. 21-33, (2007) (PubMed).
: "The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 177, Issue 1, pp. 362-71, (2006) (PubMed).
: "CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts." dans: Cancer research, Vol. 63, Issue 17, pp. 5480-9, (2003) (PubMed).
: "
-
Analysis of B-cell subpopulations in monoclonal gammopathies." dans: Clinical lymphoma, myeloma & leukemia, Vol. 15, Issue 4, pp. e61-71, (2015) (PubMed).
-
- Antigène
- CD20 (MS4A1) (Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))
- Autre désignation
- CD20 (MS4A1 Produits)
- Sujet
- MS4A1,CD20 is a cell surface 33-37 (depending on the degree of phosphorylation) kDa non-glycosylated surface phosphoprotein expressed on mature and most malignant B cells, but not stem cells or plasma cells (low number of the CD20 has been also detected on a subpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). Its expression on B cells is synchronous with the expression of surface IgM. CD20 regulates transmembrane calcium conductance (probably functioning as a component of store-operated calcium channel), cell cycle progression and B-cell proliferation. It is associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb treatment.,B1, S7, MS4A, Bp35, CVID5, LEU-16
- ID gène
- 931
- UniProt
- P11836
-